Literature DB >> 28260497

Improved Protein Toxin Delivery Based on ATTEMPTS Systems.

Yingzhi Chen1, Meng Zhang1, Kyoung Ah Min2, Huiyuan Wang1, Meong Cheol Shin3,4, Feng Li5, Victor C Yang4, Yongzhuo Huang1.   

Abstract

BACKGROUND: Ribosome-inactivating proteins (RIPs) are wildly found in multiple species of plants, bacteria and fungi. As a special family of protein toxins, RIPs can inhibit protein synthesis and induce cell death via inactivating ribosome in eukaryotic cells. Thus, RIPs have been applied for anti-tumor therapy in the past two decades. However, because of poor cell permeability, nonselective mode of action for tumor cells, poor pharmacokinetic profiles and immunogenicity, their clinical application has been severely constrained. As an effort to overcome these obstacles, tumor-specific monoclonal antibodies (mAb) have been conjugated to RIPs (forming so called "immunotoxins") specifically to increase their cytotoxicity and provide tumor targeting. Nevertheless, immunotoxins yet have not fully resolved all the issues and critical challenges still remain, such as immunogenicity and inability to penetrate into the deep site of tumor.
OBJECTIVE: To overcome the constrain of immunotoxins, the novel cell-penetrating peptide (CPP)- modified ATTEMPTS systems based on combination of CPP-mediated penetration and antibodymediated tumor targeting, with triggerable drug release function, were developed to achieve effective and safe delivery of protein toxin.
RESULTS: The CPP-modified ATTEMPTS systems showed effective protamine-triggered CPP-toxin release and thus enhanced CPP-mediated cellular uptake and cytotoxicity. It also showed antibodymediated in vivo tumor targeting and significantly increased in vivo tumor growth suppression with limited systematic toxicity.
CONCLUSION: The CPP-modified ATTEMPTS systems were developed and demonstrated as a proof-ofconcept for CPP-based protein toxin delivery with triggerable antibody targeting to improve the druggability of protein toxin drugs. The systems showed the potential application of protein toxin clinical translation in anticancer treatment. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Protein toxin; cell-penetrating peptide (CPP); gelonin; immunotoxin; ribosome-inactivating protein; tumortargetingzzm321990delivery.

Mesh:

Substances:

Year:  2018        PMID: 28260497      PMCID: PMC5581292          DOI: 10.2174/1389450118666170302094758

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  77 in total

Review 1.  How does P-glycoprotein recognize its substrates?

Authors:  K Ueda; Y Taguchi; M Morishima
Journal:  Semin Cancer Biol       Date:  1997-06       Impact factor: 15.707

2.  Synergy of sequential administration of a deglycosylated ricin A chain-containing combined anti-CD19 and anti-CD22 immunotoxin (Combotox) and cytarabine in a murine model of advanced acute lymphoblastic leukemia.

Authors:  Stefan K Barta; Yiyu Zou; John Schindler; Niraj Shenoy; Tushar D Bhagat; Ulrich Steidl; Amit Verma
Journal:  Leuk Lymphoma       Date:  2012-04-18

Review 3.  Cell-targeting fusion constructs containing recombinant gelonin.

Authors:  Mi-Ae Lyu; Yu Joshua Cao; Khalid A Mohamedali; Michael G Rosenblum
Journal:  Methods Enzymol       Date:  2012       Impact factor: 1.600

Review 4.  Immunotoxin treatment of cancer.

Authors:  Ira Pastan; Raffit Hassan; David J FitzGerald; Robert J Kreitman
Journal:  Annu Rev Med       Date:  2007       Impact factor: 13.739

5.  PTD-Modified ATTEMPTS for Enhanced Toxin-based Cancer Therapy: An In Vivo Proof-of-Concept Study.

Authors:  Meong Cheol Shin; Jian Zhang; Kyoung Ah Min; Huining He; Allan E David; Yongzhuo Huang; Victor C Yang
Journal:  Pharm Res       Date:  2015-02-21       Impact factor: 4.200

6.  Nontoxic membrane translocation peptide from protamine, low molecular weight protamine (LMWP), for enhanced intracellular protein delivery: in vitro and in vivo study.

Authors:  Yoon Jeong Park; Li-Chien Chang; Jun Feng Liang; Cheol Moon; Chong-Pyoung Chung; Victor C Yang
Journal:  FASEB J       Date:  2005-07-20       Impact factor: 5.191

7.  Photochemical internalization (PCI) of HER2-targeted toxins: synergy is dependent on the treatment sequence.

Authors:  Maria Brandal Berstad; Anette Weyergang; Kristian Berg
Journal:  Biochim Biophys Acta       Date:  2012-09-08

8.  In vitro assessment of a novel polyrotaxane-based drug delivery system integrated with a cell-penetrating peptide.

Authors:  Cheol Moon; Young Min Kwon; Won Kyu Lee; Yoon Jeong Park; Victor C Yang
Journal:  J Control Release       Date:  2007-09-05       Impact factor: 9.776

9.  Recombinant TAT-gelonin fusion toxin: synthesis and characterization of heparin/protamine-regulated cell transduction.

Authors:  Meong Cheol Shin; Jingwen Zhao; Jian Zhang; Yongzhuo Huang; Huining He; Mei Wang; Kyoung Ah Min; Victor C Yang
Journal:  J Biomed Mater Res A       Date:  2014-04-23       Impact factor: 4.396

Review 10.  Carcinoembryonic antigen in staging and follow-up of patients with solid tumors.

Authors:  A M Ballesta; R Molina; X Filella; J Jo; N Giménez
Journal:  Tumour Biol       Date:  1995
View more
  5 in total

Review 1.  Advances on Tumor-Targeting Delivery of Cytotoxic Proteins.

Authors:  Akmal M Asrorov; Zeyun Gu; Kyoung Ah Min; Meong Cheol Shin; Yongzhuo Huang
Journal:  ACS Pharmacol Transl Sci       Date:  2019-12-30

Review 2.  Toxic proteins application in cancer therapy.

Authors:  Zahra Setayesh-Mehr; Mahdiye Poorsargol
Journal:  Mol Biol Rep       Date:  2021-04-25       Impact factor: 2.316

Review 3.  The role of cell-penetrating peptides in potential anti-cancer therapy.

Authors:  Meiling Zhou; Xi Zou; Kexin Cheng; Suye Zhong; Yangzhou Su; Tao Wu; Yongguang Tao; Li Cong; Bin Yan; Yiqun Jiang
Journal:  Clin Transl Med       Date:  2022-05

Review 4.  Advances on Delivery of Cytotoxic Enzymes as Anticancer Agents.

Authors:  Akmal M Asrorov; Bahtiyor Muhitdinov; Bin Tu; Sharafitdin Mirzaakhmedov; Huiyuan Wang; Yongzhuo Huang
Journal:  Molecules       Date:  2022-06-14       Impact factor: 4.927

5.  Multi-Arm PEG/Peptidomimetic Conjugate Inhibitors of DR6/APP Interaction Block Hematogenous Tumor Cell Extravasation.

Authors:  Liting Wang; Qing Shen; Hongze Liao; Hao Fu; Qi Wang; Jian Yu; Wei Zhang; Chuanrong Chen; Yang Dong; Xupeng Yang; Qianqian Guo; Jiali Zhang; Jian Zhang; Wei Zhang; Houwen Lin; Yourong Duan
Journal:  Adv Sci (Weinh)       Date:  2021-03-18       Impact factor: 16.806

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.